enow.com Web Search

  1. Ads

    related to: castration resistant prostate cancer prognosis chart
    • Find an Imaging Site

      Locate the nearest imaging site

      or contact customer service.

    • Contact Us

      Contact our representatives

      for product and reimbursement info.

Search results

  1. Results from the WOW.Com Content Network
  2. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]

  3. Prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Prostate_cancer

    Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Some tumors metastasize (spread) to other areas of the body, particularly the bones and lymph nodes.

  4. DU145 - Wikipedia

    en.wikipedia.org/wiki/DU145

    Castration-resistant prostate cancer (CRPC) is prostate cancer that progresses despite extremely low testosterone in the body often due to medical castration. [4] Unlike many other types of prostate cancer, CRPC do not need normal testosterone levels, but they still require regular androgen receptors (AR).

  5. Prostate cancer shouldn’t be a death sentence. But for a ...

    www.aol.com/finance/prostate-cancer-shouldn-t...

    In fact, the five-year survival rate for prostate cancer detected early is virtually 100%, Siddiqui says. The outlook for late-diagnosed patients, however, is not nearly as rosy.

  6. Medical uses of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

    Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

  7. Enzalutamide - Wikipedia

    en.wikipedia.org/wiki/Enzalutamide

    Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...

  1. Ads

    related to: castration resistant prostate cancer prognosis chart